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Abstract
Background: Myelin oligodendrocyte glycoprotein (MOG) is a candidate primary target of the auto-
immune attack on the central nervous system (CNS) in multiple sclerosis (MS). However, the physio-
logical function of MOG has been unclear for a long time.
Objective: We propose that MOG has a central role in the regulation of tolerance and autoimmunity.
Conclusion: The interaction of MOG with DC-SIGN, an innate antigen receptor of myeloid antigen-
presenting cells (m-APCs), present inside the CNS (microglia) or in draining lymph nodes (dendritic
cells; DCs), keeps these cells in an immature/tolerogenic state. We postulate that this tolerogenic
mechanism may be disturbed in MS by unknown factors.
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Introduction
It has been proposed that autoimmunity in multiple
sclerosis (MS) is not caused by an exogenous factor
such as infection (outside-in), but by a dysregulated
immune reaction against damage within the central
nervous system (CNS; inside-out paradigm).1 The
cause of the injury is not known, but could be
instability of myelin-axon units, resulting in
impaired trophic support to axons by astrocyte-oli-
godendrocyte-myelin sheath complexes.2 However,
myelin degeneration per se, such as associated with
trauma or ageing or in animal models, does not inev-
itably evoke autoaggressive immunity, although this
can be observed when injury and concomitant glia
activation accumulate. Despite the massive release
of multiple myelin as well as non-myelin antigens
after traumatic brain injury, a narrow B cell response
against astrocytic glial fibrillary acidic protein
(GFAP) can be detected, but not against myelin.3
This raises the question why autoimmunity against
myelin is rare in these disorders, but commonly
observed in MS.
Here we propose the viewpoint that this can be
explained by the key homeostatic task of the CNS
myelin constituent myelin oligodendrocyte
glycoprotein (MOG), being to keep professional
antigen-presenting cells (APCs) present in the CNS
(microglia) of draining lymph nodes (dendritic cells;
DCs) in an immature/tolerogenic state. This homeo-
static function depends on the glycosylation of
MOG4 and may be disturbed by genetic or presently
unknown glia-toxic factors, which have been found
in MS patients.5
Regulation of T cell autoimmunity by myeloid
antigen presenting cells (m-APCs)
Professional APCs ingest and degrade protein anti-
gens within endolysosomal compartments, and pre-
sent degradation products (peptides) via major
histocompatibility complex (MHC) class II mol-
ecules to CD4þ T cells.6,7 APCs of the myeloid lin-
eage (m-APC), comprising DCs and macrophages
(M), and of the lymphoid lineage (B cells) are dis-
cerned. M-APCs, DCs in particular, have a key regu-
latory role in T cell tolerance and immunity against
self-antigens.8 M-APCs are located in peripheral tis-
sues (DCs), within the CNS (microglia) and in the
cervical and lumbar lymph nodes (DCs) that drain
the brain and spinal cord.9 The m-APCs continu-
ously collect antigens and cell debris from the envir-
onment and are informed via innate pathogen
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recognition receptors (PRRs) about the actions that
need to be taken. Examples of PRRs are the Toll-like
receptors (TLRs), which in general (albeit not all)
relay activation signals,10 and the C-type lectin
receptors (CLRs), which in general (albeit not all)
relay inhibitory signals.4,11 We proposed that by
integrating the strength of inhibitory and activation
signals the m-APC ‘learns’ whether an immature/
tolerogenic state should be maintained or whether
differentiation to a mature/immunogenic state is
required.12
The Yin-Yang paradigm proposed that under homeo-
static conditions (scenario 1) input signals received
via CLR counterbalance those relayed through
TLRs. In the healthy tissue TLRs activating danger
signals from pathogens (pathogen-associated
molecular patterns (PAMPS)) or cell damage
(damage-associated molecular patterns (DAMPS))
are low or absent, while CLR binding glycosylated
antigens are abundant. Conceptually, antigen presen-
tation by immature m-APCs induces regulatory T
(Treg) cells (Figure 1). In the case of threat by infec-
tion or tissue injury (scenario 2), PAMPS and
DAMPS are released and bind to TLRs, thus increas-
ing the strength of activation signals that induce DC
maturation. In the mature/immunogenic state, m-
APCs express co-stimulatory molecules for full acti-
vation of T cells together with cytokines (interleukin
(IL)-12, -23) that determine their pro-inflammatory
function. When the pathogen has been cleared, the
CLR/TLR balance and homeostasis are restored and
Figure 1. Yin-Yang concept of autoimmunity: The type of autoimmune reaction that DCs induce when presenting antigen to T
cells depends on environmental signals they receive through innate pattern recognition receptors. In the homeostatic situation
(scenario 1; no disease) antigen is sampled from the environment in the absence of danger; i.e. inhibitory signals received via CLRs
are in balance with activating signals via TLRs. The APCs remain in an immature/tolerogenic state that induces Treg! no disease
(b). When antigen is recognised in the context of danger signals relayed through TLRs (scenario 2; transient autoimmunity), the
DCs mature to an immunogenic state that activates autoaggressive T cells. When the danger has been cleared homeostasis is
restored; newly formed Treg cells dampen autoimmune process. When scenario 2 occurs in individuals with a glycosylation defect,
restoration of homeostasis and disease remission cannot occur (scenario 3; chronic autoimmunity). DCs: dendritic cells; CLRs:
C-type lectin receptors; TLRs: Toll-like receptors; APCs: antigen-presenting cells; Treg: regulatory T cells.
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remission is induced. We predicted that clinical con-
ditions affecting the normal glycosylation of tissue
antigens (scenario 3) can cause permanent instability
of the CLR/TLR equilibrium, which potentially
results in chronic T cell activation without remission.
MOG as a dominant tolerogen for CNS myelin
MOG is only expressed by oligodendrocytes within
the CNS of mammalian species. The MOG gene is
highly conserved among species and the molecule
had thus far no defined physiological function.
MOG-deficient mice develop normally without obvi-
ous abnormalities in the myelination of their CNS
axons.13 For a long time, MOG was known only as
a primary target of demyelination-inducing autoanti-
bodies.7 It is difficult to understand, however, that
without a beneficial physiological function the prom-
inent expression of MOG within a vulnerable organ
such as the brain would have survived evolutionary
selection. Such an important beneficial role was
recently found.4
MOG is produced by healthy human oligodendro-
cytes as an immunoglobulin (Ig)-like molecule deco-
rated with a fucosylated N-linked glycan attached to
the asparagine residue at position 31 within the
extracellular domain. The glycan epitope supports
recognition by the CLR DC-SIGN, which is
expressed on microglia and DCs. As DC-SIGN
does not bind to MOG-deficient myelin, MOG is
the only identified ligand of DC-SIGN in CNS
myelin. MOG exerts a potent regulatory function.
Stimulation of DCs with the TLR4 ligand bacterial
lipopolysaccharide (LPS) in the presence of myelin
particles binding via MOG to DC-SIGN induced an
anti-inflammatory state, characterised by predomin-
ant production of IL-10 and suppressed inflamma-
some formation.4 Intriguingly, co-incubation of
DCs with LPS and de-fucosylated myelin, which
abrogates DC-SIGN binding, evoked inflammasome
activation and induction of pro-inflammatory T
cells.4 These data indicate a crucial physiological
function of MOG, namely prevention of T cell auto-
immunity by dampening m-APC maturation. In line
with this concept, it was found that mice with defects
in the N-linked glycosylation of proteins spontan-
eously develop MS-like pathology and disease.14
MOG as a dominant autoimmunogen
The presence of MOG in myelin is essential for
chronic experimental autoimmune encephalomyelitis
(EAE) development in mice,15 rats16 and non-human
primates.17 Taking advantage of the phylogenetic
proximity to humans, marmoset monkeys are fre-
quently used for proof-of-principle experiments
before clinical trials are initiated in humans and
also to explore hypotheses regarding the putative
pathophysiological events leading to MS. EAE
development in marmosets immunised with human
MOG as a non-glycosylated recombinant protein in
the presence of danger signals (from heat-killed
mycobacteria in complete Freund’s adjuvant;
FA¼ IFA) involves two distinct autoimmune path-
ways.18,19 One pathway leads to brain and spinal
cord white matter inflammation via MHC class II/
Caja-DRB*W1201-restricted CD4þ T helper 1 cells
specific for the epitope MOG24-36. The second
pathway leads to demyelination of brain and spinal
cord white and grey matter via MHC class I/Caja-E-
restricted CD8þ effector memory cytotoxic T
lymphocytes (CTLs) specific for the epitope
MOG40-48. Anti-MOG B cells have different roles
in these two pathways. In the first pathway B cells
are needed for the production of anti-MOG antibo-
dies, which cause focal demyelination via mobilisa-
tion of complement and/or M.20 The second
pathway operates independently of autoantibodies;
here B cells are the requisite APCs of demyelinating
CTLs, provided that they are infected with a g1-her-
pesvirus, such as human Epstein-Barr virus (EBV) or
marmoset CalHV3.21 This recently discovered path-
way has not been found in current rodent EAE
models.
The picture changed when marmosets were immu-
nised with rhMOG formulated with incomplete FA
(IFA), which lacks detectable danger signals. In this
highly refined EAE model encephalitogenic CD4þ
T cells against MOG24-36 were activated and anti-
bodies binding CNS myelin were induced, but T cell
reactivity against the CTL epitope MOG40-48 was
undetectable.22 Nevertheless, when marmosets were
immunised with a mixture of synthetic MOG14-36
and MOG34-56 peptides in IFA, activation of ence-
phalitogenic T cells against the MOG40-48 epitope
could be detected. This finding indicates that
MOG24-36-specific CD4þ Treg cells are present
in the natural repertoire and that, when activated
by the MOG14-36 peptide, they can prevent activa-
tion of CD8þ CTL cells against the flanking epitope
MOG40-48. This phenomenon is known as linked-
suppression.
Accumulating evidence demonstrates that the non-
responsiveness of marmosets to the MOG40-48 epi-
tope is broken when the MOG40-48 epitope is pre-
sented by B cells infected with the EBV-like
lymphocryptovirus (LCV) CalHV3. This is the case
in the model induced with MOG34-56 peptide in
IFA.23 Recent work shows that LCV infection
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skews the APC function of B cells from anti-inflam-
matory/tolerogenic to pro-inflammatory/immuno-
genic by altering the processing of the MOG34-56
peptide (Jagessar et al., manuscript in preparation).
Conclusion
We propose that the explanation for the absence of
anti-myelin autoimmunity in trauma and the pres-
ence in MS may be in the inflammatory condition
of the lesion. Oligodendrocytes produce differently
glycosylated MOG under inflammatory compared to
homeostatic conditions. Alteration of the normal gly-
cosylation impairs the capacity of MOG to interact
with DC-SIGN and to keep APCs, present inside the
CNS (microglia) or in DCs, in an immature/tolero-
genic state. Due to the altered glycosylation of
MOG, activation of m-APC in CNS is induced, lead-
ing to amplification of local presentation of myelin
antigens, (re-) activation of T cells and influx of
additional cell types and soluble factors into the
CNS, which together induce full-blown MS lesion
formation.
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